Item 8.01 Other Events.

On March 28, 2023, Anebulo Pharmaceuticals, Inc. filed a Current Report on Form 8-K (the "March 8-K") that included results from its randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating ANEB-001 as a potential treatment for ACI in healthy volunteers challenged with oral delta-9-tetrahydrocannabinol. The charts contained in Exhibit 99.1 to this Current Report on Form 8-K are incorporated by reference herein and graphically present data that is consistent with the data reported in the March 8-K.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit
Number                                  Description
99.1        Part B Final Data Charts
104       Cover Page of Interactive Data File (embedded within the Inline XBRL
          document).

© Edgar Online, source Glimpses